Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
about
Galeterone for the treatment of advanced prostate cancer: the evidence to dateCYP17 inhibitors in prostate cancer: latest evidence and clinical potentialSplice Variants of Androgen Receptor and Prostate CancerTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerPersistent androgen receptor addiction in castration-resistant prostate cancerProstate Cancer Stem Cells: Research AdvancesEmerging data on androgen receptor splice variants in prostate cancerAndrogen receptor splice variants and prostate cancer: From bench to bedside.The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular DynamicsGaleterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceStructurally novel steroidal spirooxindole by241 potently inhibits tumor growth mainly through ROS-mediated mechanismsTargeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Novel agents for castration-resistant prostate cancer: Early experience and beyond.Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Progress in the mechanism and drug development of castration-resistant prostate cancer.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Androgen receptor variation affects prostate cancer progression and drug resistance.Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in miceIdentification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole CarbamateSmall Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer.Clinical relevance of androgen receptor alterations in prostate cancer.Inherent steroid 17α,20-lyase activity in defunct cytochrome P450 17A enzymes.Kinetic processivity of the two-step oxidations of progesterone and pregnenolone to androgens by human cytochrome P450 17A1.Structure-based optimisation of non-steroidal cytochrome P450 17A1 inhibitors.Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide.Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival.Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.Androgen deprivation and immunotherapy for the treatment of prostate cancerMicrowave-assisted synthesis of biologically relevant steroidal 17--pyrazol-5'-ones from a norpregnene precursor by a side-chain elongation/heterocyclization sequence
P2860
Q26739887-987F0945-E5BF-4805-A67C-012CF4973C8FQ26740070-A119B7F2-3D54-4904-A7E9-4744EFC9729CQ26740592-42104A17-7BE2-40F7-9D48-FDB2E2F20AA2Q26750620-C48D4CD4-5523-460C-9F18-9835449F7E13Q26766638-7DA26A51-71DF-4C2B-93D2-5844CC676555Q26777163-EAB6257A-1E15-4A11-A223-141CCCF2835EQ26998435-A756DA89-8FC6-4795-9E0A-F04392C25007Q28077830-DECD1945-2318-4C9D-B532-C27FDE1F1169Q33567024-5A4D9E2A-7A1B-48E4-B3C5-F4593DC360D0Q34525556-557642F7-719C-4D9D-8371-390B31C33D38Q36297428-3D7B611D-6A8B-42B7-A25F-C44E2B839ECAQ36413805-2317ADED-675D-44A7-BD5F-EB75B6CBC51BQ36470627-0F66F580-2599-45BE-A065-E36E51D5B567Q37177557-87FFA796-FB7C-4033-BD01-C43BFE5E11F6Q37496652-1358306D-B747-4B1E-8BBE-3180ECC3C042Q38574684-06637602-FD81-4867-ABB0-21D7B0042566Q38746805-A7D1391F-A133-4293-873B-ADCBE33D2403Q38765489-23A68367-C12B-4507-AB2A-5C3D6F7500E2Q38775459-B5A15D69-C0B4-43DA-8F3A-F3B6A093C67EQ38797560-6A5FBBB8-ACB6-4979-894C-8F3BFD310842Q38826609-31F675D0-7A37-4971-AAAA-BFE48B06C0A9Q38865487-F27D0347-9C0C-4337-8D6C-0F3DE8D373DEQ38977288-BEDD9209-FFBF-4C6A-ABBC-5E75FE56CC14Q41592725-307864BF-EA6A-4E3B-A425-8738079293CBQ42123839-6417E56F-0B73-475B-A705-87B6A3015DDDQ42358750-CE2558C5-822F-4B73-8256-30695950DB42Q42377108-BD90E6A2-A30C-4297-8BD2-59634893E99CQ47322511-3B48130C-FF63-47C3-9995-E34EAC710389Q48164914-BE7D2E7A-A213-4000-9208-A7F05C4F474CQ48185348-A6CD6C57-C0AA-4CE3-A6A8-7CBA25CB7B18Q48245247-77AAB491-25B4-446C-8D48-B6176DC52D23Q50925353-6A564020-5BB3-48BA-8FCA-16659F5FF95FQ55129906-BA991AD6-6E8E-4B68-8EC8-6B1DD9916FA6Q55441916-5C0177D5-16E2-42AF-805E-54ACD025BA97Q57115565-C48C4E68-3433-45CE-B9DF-0A306E3D3747Q58579904-56DE57BC-01D4-4AD0-87F7-0FD088036DB6
P2860
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Discovery and development of G ...... all stages of prostate cancer.
@en
type
label
Discovery and development of G ...... all stages of prostate cancer.
@en
prefLabel
Discovery and development of G ...... all stages of prostate cancer.
@en
P356
P1476
Discovery and development of G ...... all stages of prostate cancer
@en
P2093
Angela M H Brodie
P304
P356
10.1021/JM501239F
P407
P577
2015-01-28T00:00:00Z